Squarepoint Ops LLC Invests $223,000 in TuHURA Biosciences (NASDAQ:HURA)

Squarepoint Ops LLC acquired a new position in shares of TuHURA Biosciences (NASDAQ:HURA) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 54,535 shares of the company’s stock, valued at approximately $223,000. Squarepoint Ops LLC owned approximately 0.13% of TuHURA Biosciences as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in HURA. Geode Capital Management LLC purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $1,084,000. Suncoast Equity Management purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $421,000. Apollon Wealth Management LLC purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $253,000. Northern Trust Corp purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $234,000. Finally, Hurlow Wealth Management Group Inc. purchased a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $170,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Stock Down 2.8%

HURA opened at $2.81 on Friday. The business has a 50 day moving average price of $3.68 and a two-hundred day moving average price of $3.93. TuHURA Biosciences has a 52 week low of $1.80 and a 52 week high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of TuHURA Biosciences in a report on Friday, May 16th.

TuHURA Biosciences Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.